CLINICAL_TRIALS
ClinicalTrials.gov record update
Camrelizumab in Combination With Apatinib in in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma: a Phase Ib/II, Multicentre, Open-label, Single-arm Trial
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT04476459
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:38:16.719540+00:00
- Published At
- 2021-03-15T00:00:00+00:00
- Record Updated At
- 2021-03-15
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Diffuse Large B Cell Lymphoma", "High-grade B-cell Lymphoma", "Follicular Lymphoma Grade IIIb", "Transformed Lymphoma", "EBV-Positive DLBCL, Nos", "ALK-Positive Anaplastic Large Cell Lymphoma"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2021-03-15"- protocolSection.identificationModule.nctId
"NCT04476459"- protocolSection.identificationModule.officialTitle
"Camrelizumab in Combination With Apatinib in in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma: a Phase Ib/II, Multicentre, Open-label, Single-arm Trial"- protocolSection.statusModule.overallStatus
"UNKNOWN"- protocolSection.designModule.phases
["PHASE1", "PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.